NCT Number: NCT00084045
Voluntary HIV Counseling, Testing, and Medication for Pregnant Women to Prevent Mother-to-Child HIV Transmission
Voluntary HIV counseling and testing (VCT) and anti-HIV drugs for pregnant women and their newborns decrease rates of mother-to-child transmission (MTCT) of HIV. This study will determine the acceptability of HIV counseling and rapid testing prior to delivery and will compare the usefulness of VCT prior to birth versus after birth in preventing MTCT of HIV in pregnant women in Cape Town, South Africa. This study will also determine the acceptability and effectiveness of giving anti-HIV medications to prevent MTCT of HIV.
Looking for future studies?
Notify MeKey information
Conditions
Age range
14 year and older
Sex eligibility
Female
Study type
Interventional
Phase
Not applicable
Primary location
Hottentots Holland Hospital, Cape Town, South Africa
About this study
Pediatric HIV infection is a major public health problem in South Africa, and is primarily caused by MTCT of HIV. Strategies to prevent MTCT have been successfully employed when a mother's HIV status is known. However, there is concern in South Africa that it is unethical to offer HIV testing to women in the intrapartum period when they are experiencing the physical and emotional stress of labor. This study will compare the acceptability and accuracy of intrapartum and postpartum VCT in pregnant women of unknown HIV status in Cape Town, South Africa.
Pregnant women of unknown HIV status coming to a participating hospital to deliver will be asked to enter the trial. Women will be assigned to either intrapartum or postpartum VCT depending on the week during which they come to the hospital. The intervention (intrapartum or postpartum VCT) for the week will be randomly assigned and all women enrolling in the trial in a given week will receive the same intervention.
All women will receive HIV counseling prior to testing. Women in the intrapartum VCT group who are HIV infected will receive antiretrovirals (ARV) prior to delivery to prevent MTCT, and their infants will receive ARV within 3 days of birth. Infants born to HIV infected women in the postpartum VCT group will receive ARV as soon as possible after confirmation of the mother's positive test. All women will receive post-test counseling prior to discharge.
HIV VCT, medical history assessment, and physical exam will occur at study entry. A small subset of both HIV infected and uninfected mothers will be asked for their opinions regarding peripartum HIV VCT and MTCT prevention strategies during qualitative assessments.
Infants will undergo physical exam within 2 days of birth, medical history assessment within 2 days of birth and at 3 additional times between 6 and 14 weeks of age, and HIV testing within 2 days of birth and at 2 additional times between 6 and 12 weeks of age.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for Women:
- Unknown HIV infection status
- At least seven months pregnant
- Women in active labor who have planned induction or Caesarean delivery or any other condition requiring planned delivery
Inclusion criteria
for Infants:
- Mother is participating in study
- Mother is HIV infected
Exclusion criteria
for Women:
- Women in labor who need immediate delivery
- Obstetrical emergencies in which the woman is medically unstable or requires emergency delivery
- Diagnosed fetal death or fetal condition requiring abortion
Treatment and study plan
Postpartum HIV counseling/testing
ProcedurePrimary outcomes
-
Time required to obtain informed consent
-
time from initiation of HIV pre-test counseling until test results are available
-
proportion of test evaluations completed before delivery
-
proportion of test evaluations completed before hospital discharge
-
proportion of women who agree to HIV testing
-
proportion of women identified as HIV infected during labor who accept ARV prophylaxis
-
proportion of women identified as HIV infected after birth who accept ARV therapy for their infants
-
timing of infant ARV prophylaxis initiation after birth, as a proportion of infants born to women identified as HIV infected after birth and as a continuous variable
-
timing of mother ARV initiation as a proportion of women identified as HIV infected during labor and as a continuous variable
-
qualitative measures (defined as available space, study staff allocation, support for counseling and testing, and women's perceptions and opinions of counseling and testing)
Secondary outcomes
-
Proportion of women with undocumented HIV infection who are tested and determined to be HIV infected peripartum
-
performance of rapid HIV tests as measured by sensitivity and specificity
-
proportion of infants who complete the Week 6 study visit and efforts needed to accomplish this visit
-
proportion of infants being fed according to the method chosen at discharge (defined as exclusive breastfeeding, exclusive formula feeding, or mixed feeding), as reported by the mother at Week 6
-
proportion of HIV-exposed infants who acquire HIV infection during delivery and after birth
-
acceptance of HIV counseling and testing among clinical personnel at primary, secondary, and tertiary care facilities
Sponsors and collaborators
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Nih
Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Registry information
Official study title
Mother Infant Rapid Intervention at Delivery (MIRIAD)
Important dates
- Study start
- 2004
- Study completion
- 2006
- First posted
- Jun 7, 2004
- Registry last updated
- Oct 30, 2012
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
NCT03048422
Blood-Borne Infections, Communicable Diseases
Jacksonville, Florida, United States
View Trial DetailsA Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab
NCT05388474
Blood-Borne Infections, Communicable Diseases
Los Angeles, California, United States
View Trial DetailsSafety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine
NCT03284710
Blood-Borne Infections, Communicable Diseases
Maputo, Mozambique
View Trial DetailsSafety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection
NCT02591420
Blood-Borne Infections, Communicable Diseases
Kericho, Kenya
View Trial Details